How Nerve-Released Peptides Trigger Skin Inflammation: Mapping the Signaling Pathways in Keratinocytes
Neuropeptides substance P and CGRP activate specific MAPK signaling pathways (ERK1/2 and JNK) in skin cells to drive inflammatory cytokine and nerve growth factor production, revealing therapeutic targets for inflammatory skin diseases and pain syndromes.
Quick Facts
What This Study Found
Both substance P (SP) and CGRP concentration-dependently stimulated keratinocyte proliferation and production of IL-1β, IL-6, TNF-α, and nerve growth factor (NGF). SP activated all three MAPK families (ERK1/2, JNK, p38) plus NFκB, while CGRP activated only ERK1/2 and p38.
The study revealed several novel findings: CGRP stimulates keratinocyte expression of both CGRP itself and its receptor complex (creating an autocrine amplification loop); SP and CGRP both stimulate IL-6 and TNF-α secretion (previously unknown); SP activates all three MAPK families plus NFκB in keratinocytes; and the inflammatory mediator production driven by both neuropeptides depends specifically on ERK1/2 and JNK activation, as inhibitors of these pathways reversed the effects.
Key Numbers
How They Did This
The study used a keratinocyte cell line to perform receptor expression analysis, neuropeptide stimulation assays, proliferation measurements, cytokine/NGF expression and secretion quantification, and MAPK/NFκB signaling pathway activation studies. ERK1/2 and JNK inhibitors were used to confirm the signaling dependencies. Both substance P and CGRP were tested at varying concentrations to establish dose-response relationships.
Why This Research Matters
Many chronic skin conditions — including eczema, psoriasis, rosacea, and neurogenic inflammation — involve excessive nerve-skin signaling that drives inflammation and pain. By identifying ERK1/2 and JNK as the specific pathways through which neuropeptides drive keratinocyte inflammation, this study points to concrete drug targets. The discovery of the autocrine amplification loop (neuropeptides causing cells to make more neuropeptides and receptors) also explains how localized nerve irritation can escalate into widespread skin inflammation.
The Bigger Picture
The nerve-skin axis is increasingly recognized as a driver of inflammatory disease. CGRP has already become a major therapeutic target — anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) are FDA-approved for migraine prevention. This study extends the understanding of neuropeptide signaling to skin cells specifically, and the MAPK pathway dependence it identifies could inform the development of topical therapies that interrupt neurogenic inflammation at the skin level rather than systemically blocking neuropeptides.
What This Study Doesn't Tell Us
The study used a keratinocyte cell line rather than primary keratinocytes or intact skin, which may not fully replicate the complexity of in vivo neuropeptide-keratinocyte interactions. Rat-derived cells were used, and species differences in neuropeptide signaling may exist. The study did not test whether ERK1/2 or JNK inhibition would reduce inflammation in animal models of skin disease. The role of other cell types present in skin (immune cells, fibroblasts, endothelial cells) was not addressed.
Questions This Raises
- ?Would topical ERK1/2 or JNK inhibitors effectively reduce neurogenic skin inflammation in vivo without systemic side effects?
- ?Does the neuropeptide amplification loop (keratinocytes producing SP and CGRP in response to neuropeptide stimulation) occur in human skin, and does it drive flares in conditions like psoriasis?
- ?Could combined SP and CGRP receptor antagonists be more effective than targeting either neuropeptide alone for inflammatory skin conditions?
Trust & Context
- Key Stat:
- ERK1/2 and JNK inhibitors reversed neuropeptide-driven inflammation Blocking these two specific signaling pathways stopped substance P and CGRP from driving inflammatory cytokine and nerve growth factor production in keratinocytes
- Evidence Grade:
- This is a preclinical in vitro study using a keratinocyte cell line with well-controlled experiments including dose-response analyses and specific pathway inhibitors. The findings are mechanistically robust but limited to cell culture conditions without in vivo validation.
- Study Age:
- Published in 2013, this study is over a decade old. Since then, anti-CGRP therapies have become clinically successful for migraine, validating the importance of neuropeptide signaling. The MAPK pathway findings remain relevant for developing skin-specific anti-inflammatory approaches.
- Original Title:
- Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways.
- Published In:
- Regulatory peptides, 186, 92-103 (2013)
- Authors:
- Shi, Xiaoyou, Wang, Liping, Clark, J David, Kingery, Wade S
- Database ID:
- RPEP-02284
Evidence Hierarchy
Frequently Asked Questions
What are substance P and CGRP, and why are they important for skin health?
Substance P and CGRP are neuropeptides — small signaling molecules released by nerve endings in the skin. They help nerves communicate with skin cells and play roles in wound healing, blood flow, and immune defense. However, when overactive, they can drive excessive inflammation and pain, contributing to conditions like eczema, psoriasis, and chronic pain syndromes. This study shows exactly how they trigger inflammation in skin cells.
Could this research lead to new treatments for skin conditions?
Yes — the study identified two specific signaling pathways (ERK1/2 and JNK) as the bottleneck through which neuropeptides cause skin inflammation. Blocking these pathways reversed the inflammatory response in cell culture. This suggests that topical creams or other skin-targeted therapies inhibiting these pathways could potentially treat inflammatory skin diseases driven by nerve-skin crosstalk, without the need for systemic drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02284APA
Shi, Xiaoyou; Wang, Liping; Clark, J David; Kingery, Wade S. (2013). Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways.. Regulatory peptides, 186, 92-103. https://doi.org/10.1016/j.regpep.2013.08.001
MLA
Shi, Xiaoyou, et al. "Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways.." Regulatory peptides, 2013. https://doi.org/10.1016/j.regpep.2013.08.001
RethinkPeptides
RethinkPeptides Research Database. "Keratinocytes express cytokines and nerve growth factor in r..." RPEP-02284. Retrieved from https://rethinkpeptides.com/research/shi-2013-keratinocytes-express-cytokines-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.